

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5584269

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CLODAGH O'SHEA	04/12/2018
COLIN POWERS	07/05/2018
LEI ZHANG	04/06/2018
RECEIVING PARTY DATA	
Name:	SALK INSTITUTE FOR BIOLOGICAL STUDIES
Street Address:	10010 N. TORREY PINES ROAD
City:	LA JOLLA
State/Country:	CALIFORNIA
Postal Code:	92037-1002
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16434714
CORRESPONDENCE DATA	
Fax Number:	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5035955300
Email:	gina.horton@klarquist.com
Correspondent Name:	JODI L. CONNOLLY, KLARQUIST SPARKMAN LLP
Address Line 1:	121 SW SALMON ST., SUITE 1600
Address Line 2:	ONE WORLD TRADE CENTER
Address Line 4:	PORTLAND, OREGON 97204-2927
ATTORNEY DOCKET NUMBER:	7158-96599-03
NAME OF SUBMITTER:	JODI L. CONNOLLY
SIGNATURE:	/Jodi L. Connolly/
DATE SIGNED:	06/21/2019
Total Attachments: 4	
source=96599-03_Assignment#page1.tif	
source=96599-03_Assignment#page2.tif	
source=96599-03_Assignment#page3.tif	

ASSIGNMENT

We, Clodagh O'Shea, of San Diego, CA, a citizen of the United States of America, Colin Powers, of San Diego, CA, a citizen of the United States of America, and Lei Zhang, of San Diego, CA, a citizen of People's Republic of China have invented TUMOR-TARGETING SYNTHETIC ADENOVIRUSES AND USES THEREOF for which the following patent applications have been filed:

U.S. Provisional Patent Application No. 62/433,140, filed on December 12, 2016;
and
PCT Application No. PCT/US2017/065604 filed on December 11, 2017

which applications are collectively referred to herein as "the patent applications."

The subject invention(s) was made as a result of our activities at or on behalf of the Salk Institute for Biological Studies or as a result of our utilization of information, facilities or other resources of the Salk Institute for Biological Studies. The conditions under which said invention(s) was made are such as to entitle the Salk Institute for Biological Studies to the entire right, title, and interest in the invention(s) and the patent applications in the United States and its territories and dependencies, and all other countries of the world.

In consideration of our obligations and other valuable consideration, we the undersigned hereby sell, assign, and transfer to the Salk Institute for Biological Studies (hereinafter, "Salk Institute"), its successors and assigns, the full and exclusive right, title, and interest in the invention(s) and the patent applications throughout the United States of America and its territories and dependencies, and all other countries of the world. This includes an assignment of all Letters Patent that may be granted on the invention(s) in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the patent applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to the Salk Institute as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.


We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to the Salk Institute, its representatives, successors, assigns, or agents, any facts known to us respecting the invention(s), and testify in any legal proceedings, sign all lawful papers, execute all


divisional, continuing, and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid the Salk Institute, its representatives, successors, assigns, or agents to obtain and enforce proper patent protection for the invention(s) in the United States or any foreign country. These provisions are binding upon our heirs, legal representatives, administrators and assigns.

IN TESTIMONY WHEREOF, the Assignors have signed their names on the dates indicated.

Dated: April 12 2018


Clodagh O'Shea

In the presence of:


Witness Signature
JAN SCROZYNSKI
Witness Name (print)

April 12 2018
Date Signed

Dated: _____

Colin Powers

In the presence of:

Witness Signature


Witness Name (print)

Date Signed

Dated: 4/6/2018


Lei Zhang

In the presence of:


Witness Signature
LESLIE Schmitt
Witness Name (print)

4/6/18
Date Signed

ASSIGNMENT

We, Clodagh O'Shea, of San Diego, CA, a citizen of the United States of America, Colin Powers, of San Diego, CA, a citizen of the United States of America, and Lei Zhang, of San Diego, CA, a citizen of People's Republic of China have invented TUMOR-TARGETING SYNTHETIC ADENOVIRUSES AND USES THEREOF for which the following patent applications have been filed:

U.S. Provisional Patent Application No. 62/433,140, filed on December 12, 2016;
and
PCT Application No. PCT/US2017/065604 filed on December 11, 2017

which applications are collectively referred to herein as "the patent applications."

The subject invention(s) was made as a result of our activities at or on behalf of the Salk Institute for Biological Studies or as a result of our utilization of information, facilities or other resources of the Salk Institute for Biological Studies. The conditions under which said invention(s) was made are such as to entitle the Salk Institute for Biological Studies to the entire right, title, and interest in the invention(s) and the patent applications in the United States and its territories and dependencies, and all other countries of the world.

In consideration of our obligations and other valuable consideration, we the undersigned hereby sell, assign, and transfer to the Salk Institute for Biological Studies (hereinafter, "Salk Institute"), its successors and assigns, the full and exclusive right, title, and interest in the invention(s) and the patent applications throughout the United States of America and its territories and dependencies, and all other countries of the world. This includes an assignment of all Letters Patent that may be granted on the invention(s) in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the patent applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to the Salk Institute as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to the Salk Institute, its representatives, successors, assigns, or agents, any facts known to us respecting the invention(s), and testify in any legal proceedings, sign all lawful papers, execute all

divisional, continuing, and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid the Salk Institute, its representatives, successors, assigns, or agents to obtain and enforce proper patent protection for the invention(s) in the United States or any foreign country. These provisions are binding upon our heirs, legal representatives, administrators and assigns.

IN TESTIMONY WHEREOF, the Assignors have signed their names on the dates indicated.

Dated: _____

Clodagh O'Shea


In the presence of:

Witness Signature

Date Signed


Witness Name (print)

Dated: 7/5/18



Colin Powers

In the presence of:



Witness Signature

7/5/18

Date Signed

Julie Powers

Witness Name (print)

Dated: _____

Lei Zhang

In the presence of:

Witness Signature

Date Signed

Witness Name (print)